Ambalal Sarabhai Enterprises (AMBALALSA)₹36.00+0.47%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Ambalal Sarabhai Enterprises reported sales of ₹43.48 Cr, up 7.9% from Jun 2025, and net profit of ₹3.99 Cr, down 51.5% year on year. For the year to Mar 2026, sales were ₹202 Cr and net profit ₹18.03 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39.97 | 43.01 | 54.25 | 40.64 | 44.60 | 45.90 | 64.75 | 40.30 | 44.38 | 51.90 | 65.41 | 43.48 |
| Expenses | 38.87 | 40.42 | 49.55 | 40.09 | 41.98 | 46.53 | 59.28 | 38.77 | 43.93 | 47.78 | 59.59 | 38.87 |
| Operating Profit | 1.02 | 2.54 | 4.66 | 0.48 | 2.55 | −0.71 | 5.31 | 1.47 | 0.37 | 4.09 | 5.71 | 4.56 |
| OPM % | 2.5% | 5.9% | 8.5% | 1.1% | 5.7% | −1.5% | 8.2% | 3.6% | 0.8% | 7.8% | 8.7% | 10.4% |
| Other Income | 2.84 | 1.64 | 4.78 | 2.31 | 2.79 | 5.75 | −5.36 | 8.35 | 1.61 | 1.93 | 3.01 | 2.45 |
| Interest | 0.91 | 0.98 | 0.89 | 0.94 | 1.21 | 1.13 | 0.95 | 1.00 | 0.95 | 0.69 | 1.41 | 0.97 |
| Depreciation | 1.13 | 1.12 | 0.24 | 0.97 | 1.00 | 0.98 | 1.01 | 0.87 | 1.05 | 0.95 | 1.04 | 1.34 |
| Profit before tax | 1.81 | 2.03 | 8.30 | 0.83 | 3.12 | 2.92 | −2.04 | 7.94 | −0.05 | 4.37 | 6.26 | 4.67 |
| Tax % | 40.1% | 34.4% | −8.7% | 59.6% | 15.8% | 23.9% | −86.8% | −3.6% | 1,300.0% | 16.5% | −4.0% | 15.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −6.01 | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 |
| Net Profit | 1.09 | 1.34 | 9.04 | 0.36 | 2.63 | 2.24 | −0.28 | 8.23 | −0.57 | 3.65 | 6.51 | 3.99 |
| EPS (Rs) | 0.13 | 0.16 | 1.17 | 0.04 | 0.33 | 0.28 | −0.03 | 1.06 | −0.06 | 0.46 | 0.84 | 0.51 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 132 | 134 | 125 | 150 | 133 | 163 | 197 | 170 | 173 | 196 | 202 | 205 |
| Expenses | 145 | 136 | 137 | 144 | 135 | 164 | 170 | 161 | 167 | 186 | 189 | 190 |
| Operating Profit | −13.03 | −3.01 | −12.02 | 6.01 | −3.01 | −2.01 | 25.06 | 8.01 | 6.01 | 9.03 | 12.03 | 14.73 |
| OPM % | −10.0% | −2.1% | −9.0% | 3.9% | −2.5% | −0.9% | 13.0% | 5.0% | 3.4% | 4.6% | 6.0% | 7.2% |
| Other Income | 94.92 | −1.99 | 24.99 | 8.01 | 24.01 | 39.97 | 32.99 | 11.99 | 9.99 | 4.99 | 14.99 | 9.00 |
| Interest | 3.99 | 4.99 | 2.99 | 2.99 | 3.99 | 2.99 | 1.99 | 2.99 | 5.98 | 4.98 | 3.99 | 4.02 |
| Depreciation | 16.95 | 3.98 | 1.99 | 1.99 | 2.99 | 1.99 | 1.99 | 2.99 | 3.99 | 3.98 | 3.98 | 4.38 |
| Profit before tax | 61.95 | −13.99 | 8.01 | 7.99 | 15.01 | 32.98 | 54.01 | 15.01 | 7.01 | 4.99 | 19.01 | 15.25 |
| Tax % | 22.1% | 34.1% | 84.1% | 48.0% | 6.0% | 10.0% | 13.1% | 25.1% | 15.1% | −2.0% | 4.0% | — |
| Exceptional items | 79.13 | −7.01 | 10.01 | 0.00 | 0.00 | 18.05 | 12.03 | 0.00 | 0.00 | −5.01 | −1.01 | −1.01 |
| Net Profit | 48.13 | −18.05 | 1.01 | 4.01 | 14.03 | 29.06 | 47.10 | 11.03 | 6.01 | 5.01 | 18.03 | 13.58 |
| EPS (Rs) | 6.27 | −2.37 | 0.16 | 0.54 | 1.82 | 3.82 | 6.15 | 1.48 | 0.73 | 0.63 | 2.31 | 1.75 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 76.85 | 76.82 | 76.88 | 76.91 | 76.82 | 76.90 | 76.88 | 76.87 | 76.85 | 76.84 | 76.91 | 76.87 |
| Reserves | −85.86 | −37.95 | −50.93 | −49.92 | −45.96 | −31.97 | −2.99 | 42.91 | 53.96 | 59.90 | 62.91 | 81.91 |
| Borrowings | 45.86 | 46.83 | 41.84 | 42.84 | 39.84 | 30.90 | 27.87 | 26.91 | 44.86 | 45.83 | 50.80 | 56.75 |
| Other Liabilities | 132 | 93.77 | 92.79 | 128 | 144 | 111 | 108 | 83.83 | 69.72 | 66.74 | 78.62 | 64.72 |
| Total Liabilities | 169 | 179 | 160 | 196 | 213 | 186 | 209 | 231 | 245 | 249 | 269 | 279 |
| Fixed Assets | 90.79 | 71.85 | 71.85 | 58.86 | 57.83 | 56.88 | 56.82 | 57.84 | 84.80 | 87.78 | 86.80 | 88.76 |
| CWIP | 0.99 | 8.98 | 2.99 | 13.95 | 23.94 | 0.00 | 0.99 | 11.97 | 3.99 | 0.00 | 0.00 | 3.99 |
| Investments | 1.01 | 8.02 | 5.01 | 5.01 | 9.02 | 18.05 | 27.05 | 33.09 | 32.09 | 29.05 | 32.06 | 32.07 |
| Other Assets | 75.77 | 91.62 | 79.73 | 119 | 123 | 110 | 124 | 128 | 125 | 132 | 150 | 154 |
| Inventories | 17.02 | 14.36 | 13.76 | 14.34 | 14.93 | 16.39 | 15.90 | 15.08 | 17.37 | 16.12 | 23.54 | 22.15 |
| Trade receivables | 25.38 | 30.19 | 29.02 | 34.24 | 34.80 | 28.90 | 38.94 | 28.15 | 27.41 | 26.33 | 44.29 | 47.84 |
| Cash & equivalents | 13.86 | 16.42 | 16.73 | 22.09 | 23.29 | 21.55 | 31.41 | 28.28 | 28.13 | 32.95 | 11.53 | 19.42 |
| Total Assets | 169 | 179 | 160 | 196 | 213 | 186 | 209 | 231 | 245 | 249 | 269 | 279 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −8.03 | −75.22 | 5.02 | −7.02 | 19.06 | −7.03 | −2.01 | 11.04 | 6.02 | 9.03 | −18.06 | 13.05 |
| Cash from investing activity | 10.02 | 80.24 | −3.01 | 18.06 | −9.02 | 17.04 | 10.02 | 5.01 | −17.04 | −5.01 | 13.03 | −10.03 |
| Cash from financing activity | −1.01 | −3.01 | −6.02 | −2.01 | −6.02 | −14.05 | −6.02 | −19.07 | 9.02 | −3.01 | −2.01 | −2.01 |
| Net cash flow | 0.99 | 1.99 | −3.99 | 7.97 | 2.99 | −3.99 | 1.99 | −2.99 | −1.99 | 0.99 | −5.98 | 0.99 |
| Capex | 2.32 | 14.12 | 5.08 | 11.76 | 10.42 | 3.69 | 2.47 | 14.36 | 20.74 | 2.92 | 2.73 | 6.08 |
| Free cash flow | 0.99 | 12.01 | 0.99 | 8.01 | 9.01 | −10.01 | 6.99 | 15.99 | −15.01 | 5.99 | −19.99 | 6.99 |
| CFO / OP % | 89.9% | 550.9% | −252.1% | −107.1% | 452.9% | 133.9% | 22.0% | 59.9% | 119.9% | 216.9% | −160.1% | 107.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 74 | 83 | 79 | 100 | 84 | 79 | 87 | 52 | 59 | 55 | 82 | 86 |
| Inventory days | 85 | 71 | 65 | 74 | 60 | 75 | 57 | 47 | 61 | 57 | 74 | 67 |
| Days payable | 138 | 134 | 137 | 206 | 190 | 183 | 183 | 150 | 130 | 132 | 157 | 124 |
| Cash conversion cycle | 23 | 21 | 7 | −31 | −45 | −28 | −38 | −49 | −9 | −18 | −1 | 31 |
| Working capital days | −317 | −155 | −184 | −186 | −189 | −139 | −87 | −24 | −42 | −34 | −24 | 14 |
| ROCE % | −18.9% | −43.9% | −1.0% | −5.0% | 16.1% | 25.1% | 18.1% | 34.1% | 11.1% | 7.0% | 9.1% | 12.1% |
For the Jun 2026 quarter, Ambalal Sarabhai Enterprises reported sales of ₹43.48 Cr, up 7.9% year on year and net profit of ₹3.99 Cr, down 51.5% year on year. The operating margin was 10.4%.
Ambalal Sarabhai Enterprises' sales for the year to Mar 2026 were ₹202 Cr; over the last twelve months they were ₹205 Cr.
Net profit for the year to Mar 2026 was ₹18.03 Cr, and ₹13.58 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.75.
Ambalal Sarabhai Enterprises reported borrowings of ₹56.75 Cr at Mar 2026, against cash and equivalents of ₹19.42 Cr.
Cash from operations was ₹13.05 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹6.99 Cr.